The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2019) suggest that overall cancer risk is not linked to tumour necrosis factor inhibitor (TNFi) use in psoriatic arthritis. Press conference title (full): Incidence of cancer in TNFi treated patients with psoriatic arthritis: a population-based cohort study from 4 Nordic countries.
Spokesperson: Professor Lene Dreyer. Aalborg University and Aalborg University Hospital, Aalborg, Denmark. DANBIO, Nationwide, Denmark.
Abstract number: OP0005
0 Comments